MGMT and glioblastoma: These cells bear a p53 mutation and a high MGMT activity and, as demonstrated in a recent paper, these genomic characteristics make them more resistance to Temozolomide (TMZ) treatment as compared to other GBM cells, such as A172 cells [84].